Le Dr Tahsin Ozadli est spécialisé en oncologie médicale, avec une formation approfondie à l'hôpital d'oncologie d'Ankara.
Le professeur Keil est spécialisé dans l'imagerie par coupes et la radiologie interventionnelle, appliquant des techniques avancées telles que l'IRM, le scanner et l'échographie pour une planification précise des diagnostics et des traitements.
Le Dr Levin dirige le programme des sarcomes pédiatriques au centre médical Sourasky et a étudié à l'Institut orthopédique Rizzoli en Italie, chef de file mondial.
Le Prof. Dr Ozcan Yildiz possède plus de dix ans de recherche spécialisée et de publications sur des cas oncologiques complexes. Il traite les patients à l'hôpital universitaire Medipol Mega.
Le professeur Köstler est un oncologue médical distingué, spécialisé dans les thérapies ciblées, avec plus de 20 ans d'expérience dans les cancers du sein et gynécologiques à la Wiener Privatklinik.
Plus de 30 ans d'expérience en immunologie – Le Dr Jaunalksne se spécialise dans la virothérapie, une approche de pointe pour la modulation du système immunitaire.
Le Dr Alemdar se spécialise en oncologie médicale avec une formation approfondie à l'Université d'Akdeniz, une institution de premier plan en Turquie.
Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at Liv Hospital Topkapı. He specializes in treating colon, breast, gastric, and lung cancers. He previously served as the Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital. Dr. Atci is a member of the American Society of Clinical Oncology (ASCO).
Dr. Irfan Cicin is a Professor of Medical Oncology at İstinye University Liv Hospital Topkapı. He specializes in treating complex cancers, including glioblastoma, lung cancer, and pancreatic tumors. He serves as a professor at the Trakya University Faculty of Medicine. Dr. Cicin previously served as a physician in the Turkish Air Force.
Le Pr. agrégé Nail Paksoy est spécialisé dans le léiomyosarcome à l'hôpital Medipol Bahcelievler, avec une certification de l'ESMO en oncologie médicale.
Dr. Mariam Abu Zeid is a clinical oncologist at Shefaa Al Orman International Oncology Hospitals. She is certified by the European Society for Medical Oncology. Dr. Abu Zeid treats solid tumors and hematologic cancers. She holds a Ph.D. in Clinical Oncology and Nuclear Medicine from Ain Shams University.
Dr. Atakan Topcu is a medical oncologist at Medipol Acibadem District Hospital in Istanbul. He specializes in treating solid tumors including lung, breast, and colorectal cancers. Dr. Topcu is an Associate Professor with over 50 peer-reviewed scientific publications. He sits on the Editorial Board of the medical journal BMC Cancer.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Dr. Mohamed Mahmoud Abdelhakim is a Professor of Radiation Oncology at Cairo University’s National Cancer Institute. He serves as the Head of Radiation Oncology at Shefa al Orman Hospital. Dr. Abdelhakim treats complex cancers, including breast, soft tissue sarcoma, and gynecologic tumors. He is a member of ESTRO and ESMO.
Dr. Maha Yahia is a medical and hemato-oncologist at Shefaa Al Orman International Oncology Hospitals. She served as a Lieutenant Colonel physician in the Egyptian Armed Forces Medical Corps. Dr. Yahia specializes in treatment planning for breast, thoracic, and gastrointestinal cancers. She focuses on immunotherapy, targeted therapy, and complex chemotherapy protocols.
Dr. Emad Shash is a medical oncologist who has participated in over 70 oncology clinical trials. He serves as the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. Dr. Shash specializes in systemic therapies, including chemotherapy, targeted therapy, and immunotherapy. He holds a Diploma in Hospital Quality Management and Patient Safety from JCI.
Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.
He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.
Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.